Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).

Trial Details

NCT ID
NCT06865339
Phase
PHASE2
Sponsor
Montefiore Medical Center
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Cemiplimab
  • Fianlimab
  • Radiotherapy
  • Platinum Doublet Chemotherapy (PDC)
Locations (sample)
  • The Bronx, New York, United States|40.84985,-73.86641

Key Eligibility Criteria

  • Previously untreated and biopsy-proven NSCLC, with measurable disease (at least 1 unidimensional, radiographically measurable lesion based on RECIS…
  • AJCC version 8 Stage II disease, medically or technically unresectable
  • AJCC version 8 Stage III disease, eligible for non-surgical treatment
  • Determination of PD-L1 expression on pretreatment tumor specimen using a clinically validated assay

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →